NeoGenomics Q3 2025 Earnings Release

NeoGenomics, Inc. reported its third quarter 2025 financial results, showing a 12% year-over-year increase in total revenue to $188 million. Clinical revenue grew by 18%, driven by a 24% increase in NGS revenue, which now accounts for nearly one-third of clinical revenue. Despite the revenue growth, the company reported a net loss of $27 million, a 53% increase from the previous year. Adjusted EBITDA was $12.2 million, a 9% decline from the prior year. The company re-affirmed its full-year 2025 guidance, expecting consolidated revenue between $720 million and $726 million, net loss between $116 million and $108 million, and adjusted EBITDA between $41 million and $44 million. CEO Tony Zook highlighted the company's focus on therapy selection and MRD as key growth areas.